Asterias Biotherapeutics, Inc. AST was a big mover last session, as its shares rose almost Array8% on the day. The upside might have been driven by the appointment of pharmaceutical industry veteran Stephen L. Cartt as President and CEO and Don M. Bailey to the company's board. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend of the company, as the stock is now trading above the volatile trend of $2.95 to $3.87 in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Asterias Biotherapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #Array (Strong Buy).
Is AST going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment